Table 1 Baseline characteristics of the study cohort
Variables | White blood cell, 109/L | |||||
|---|---|---|---|---|---|---|
All | Quartile 1 (<5.0) | Quartile 2 (5.0–6.0) | Quartile 3 (6.0–7.0) | Quartile 4 (≥7.0) | P-trend | |
N = 3768 | N = 835 | N = 1047 | N = 925 | N = 961 | ||
Age, year | 56.6 (8.5) | 56.3 (8.0) | 56.5 (8.5) | 56.9 (8.5) | 56.8 (9.0) | 0.149 |
Males, n (%) | 1352 (35.9%) | 203 (24.3%) | 356 (34.0%) | 336 (36.3%) | 457 (47.6%) | <0.001 |
White blood cell, 109/L | 6.1 (1.5) | 4.4 (0.5) | 5.5 (0.3) | 6.4 (0.3) | 8.2 (1.2) | <0.001 |
Body mass index, kg/m2 | 26.0 (3.4) | 25.3 (3.3) | 25.9 (3.2) | 26.2 (3.4) | 26.6 (3.4) | <0.001 |
eGFR, mL/min/1.73m2 | 101.1 (10.6) | 101.9 (10.1) | 101.4 (10.0) | 101.0 (10.6) | 100.2 (11.8) | 0.001 |
Current smoking status, n (%) | 709 (18.8%) | 82 (9.8%) | 164 (15.7%) | 168 (18.2%) | 295 (30.7%) | <0.001 |
Current drinking status, n (%) | 868 (23.0%) | 145 (17.4%) | 257 (24.5%) | 221 (23.9%) | 245 (25.5%) | <0.001 |
Prevalence of disease, n (%) | ||||||
Hypertension | 1833 (48.6%) | 355 (42.5%) | 500 (47.8%) | 466 (50.4%) | 512 (53.3%) | <0.001 |
Diabetes mellitus | 654 (17.4%) | 105 (12.6%) | 153 (14.6%) | 167 (18.1%) | 229 (23.8%) | <0.001 |
Dyslipidemia | 2768 (75.1%) | 567 (69.6%) | 739 (72.3%) | 709 (78.4%) | 753 (79.8%) | <0.001 |
Cardiovascular disease | 477 (12.7%) | 82 (9.8%) | 119 (11.4%) | 132 (14.3%) | 144 (15.0%) | <0.001 |
Treatment, n (%) | ||||||
Antihypertensive | 1183 (31.6%) | 197 (23.8%) | 323 (31.0%) | 315 (34.2%) | 348 (36.4%) | <0.001 |
Hypoglycemic | 382 (10.2%) | 62 (7.4%) | 88 (8.4%) | 105 (11.4%) | 127 (13.3%) | <0.001 |
Lipid-lowering | 397 (10.6%) | 59 (7.1%) | 104 (10.0%) | 109 (11.9%) | 125 (13.1%) | <0.001 |